ClinicalTrials.gg
Active, not recruitingNCT07904247CANCERUpdated Oct 29, 2026

CANCER SCREENING PROGRAM ON UNCERTAINTY, ANTİCİPATORY ANXIETY, CANCER AWARENESS, AND E-HEALTH LITERACY IN A STROKE PATIENTS

An interventional study of CANCER SCREENING PROGRAM in Cancer and Stroke, sponsored by Ondokuz Mayıs University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2025, registered Jun 2026).
Updated Oct 29, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This research aims to evaluate the impact of a cancer awareness education program (Cancer Awareness Programme Via Digital Health Literacy - DigiCAP), designed to enhance digital literacy and applied to stroke patients, on uncertainty, anticipatory anxiety, and cancer awareness. This study was designed as a randomized controlled, single-blind (evaluator-blind), pre-test-post-test experimental design. In the study, all individuals in the sample group were administered the Personal Information Form, the Mishel Illness Uncertainty Scale-Community Form (MIIS-T), the Beck Anxiety Scale (BAS), and the E-Health Literacy Scale as pre-test applications. The training program prepared for the experimental group will be presented. Final tests will be conducted at the end of the training. Individuals will be contacted by phone one month after the training for reminder purposes. Individuals are expected to participate in cancer screening within 3 months.

Read the detailed description

This study was planned in accordance with a single-blind randomized controlled pre-test-post-test experimental research design. The population of the study will consist of individuals diagnosed with stroke who are registered in the Home Care Unit of Amasya Merzifon Kara Mustafa Paşa State Hospital and receiving home care between January 1, 2025 and January 1, 2026. The sample of the study will consist of individuals diagnosed with stroke who are registered in the home care unit, meet the research criteria, and agree to participate in the study. Inclusion Criteria

  • Having a stroke diagnosis,
  • Being 50 years of age or older,
  • Being literate,
  • Patients diagnosed with stroke who can communicate will be included in the study. • Having a smartphone or computer,
  • Having internet access. • Having a diagnosis of ischemic stroke,
  • Caregiver screening awareness? Establishing criteria for caregivers (separate headings) 2.5. Exclusion Criteria
  • Impairment of vision, hearing, and speech due to stroke,
  • Having any health problem that hinders cognitive and mental communication (dementia, history of psychiatric illness that would impede communication, etc.)
  • Having been diagnosed with cancer. Patients diagnosed with stroke in the sample were randomly assigned to intervention and control groups using a simple randomization method. The assignment ratio of patients to the groups was determined as 1:1. The SAS 9.4 software package was used for the randomization of patients to the groups. The blinding of the study was ensured by randomly assigning individuals diagnosed with stroke to the groups. Participants were unaware of which group they were in. In the statistical evaluation phase, the data were divided into two datasets, A and B, and presented to an independent statistician for evaluation. Since the statistician did not know which group was the experimental or control group, statistician blinding was also performed. The research data will be collected using a Personal Information Form, the Mishel Illness Uncertainty Scale, the Beck Anxiety Scale, and the e-Health Literacy Scale. A training booklet will be distributed to participants during the training. The training, planned to strengthen digital literacy, consists of 5 sections. These sections will cover program introduction, digital health literacy, stroke, cancer, and stress management, as outlined below. The total training duration is 55 minutes, with 5-minute breaks. Post-training tests will be administered to participants. Participants will receive reminder calls one month after the training. Participants are expected to attend cancer screenings within 3 months. After the data collection process is complete, a control group will also receive training and a training booklet for ethical reasons.
02

Conditions studied

  • Cancer
  • Stroke

Keywords

  • STROKE
  • CANCER
  • CANCER SCREENİNG
  • E-HEALTH LİTERACY
03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 88 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Ondokuz Mayıs University is the lead sponsor of 277 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Having been diagnosed with a stroke,

      • Being 50 years of age or older,
      • Being literate,
      • Patients with a stroke who are able to communicate will be included in the study. • Having a smartphone or computer,
      • Having internet access. • Having been diagnosed with an ischemic stroke,

Exclusion criteria

Exclusion Criteria:

    • Having impaired vision, hearing, and speech due to a stroke,

      • Having any health problem that hinders cognitive and mental communication (dementia, a history of psychiatric illness that impedes communication, etc.),
      • Having been diagnosed with cancer.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    A CANCER SCREENING PROGRAM

    The data for the study were collected at Merzifon Kara Mustafa Paşa State Hospital in Merzifon district of Amasya province, and were completed with 44 individuals in the experimental group and 44 individuals in the control group who met the inclusion criteria. In the study, all individuals in the sample group were administered the Personal Information Form, the Mishel Illness Uncertainty Scale-Community Form (MIIS-T), the Beck Anxiety Scale (BAS), and the E-Health Literacy Scale as pre-test applications. The Personal Information Form, Michel Illness Uncertainty Scale-Community Form (MIIS-T), Beck Anxiety Scale (BAS), and E-Health Literacy Scale were administered to individuals diagnosed with stroke in the experimental group.

    Behavioral: CANCER SCREENING PROGRAM

  • No intervention
    CONTROL GROUP

    Following the completion of the data collection process, participants in the control group will receive the same training through home visits and will be given the training booklet. This practice aims to ensure that participants in the control group also benefit from the training, as an ethical requirement.

Interventions

  • BehavioralCANCER SCREENING PROGRAM

    During home visits, written informed consent will be obtained, the study protocol will be explained, and pre-tests will be administered. Individuals who undergo the pre-test will be randomly assigned to experimental and control groups using a simple random sampling method. The experimental group will receive the planned training, and a training booklet will be provided at the end of the training. One month after the completion of the training, individuals will be visited again at their homes to remind them of their participation in the cancer screening program, and post-tests will be administered. Three months after the start of the study, statements will be obtained from the phone numbers on the patient list to determine whether the experimental group participated in cancer screenings.

06

What researchers measure

Primary outcomes

  1. DATA COLLECTION

    Michel Illness Uncertainty Scale-Community Form (IID-T): The scale is evaluated based on three sub-dimensions: "perception of current situation," "perception of understanding," and "uncertainty," and a total score. The scale score is obtained by summing the points given to each item. The possible score ranges from 20 to 100. A higher score indicates increased illness uncertainty.

    Time frame: about 3 months from the initial stage

  2. DATA COLLECTION

    Cancer Fear Scale (CFS): This scale consists of 17 items and 2 sub-dimensions: direct fear and indirect fear. The possible total score ranges from 0 to 68. Higher scores indicate a higher level of cancer fear.

    Time frame: about 3 months from the initial stage

  3. DATA COLLECTION

    e-Health Literacy Scale (e-Health Literacy): This scale consists of eight items measuring internet attitudes, two of which assess internet use. The lowest possible score is 8, and the highest is 40. A high score indicates a high level of e-health literacy.

    Time frame: about 3 months from the initial stage

07

Study locations

1 site
  • Merzifon Kara Mustafa Paşa Devlet Hastanesi
    Amasya, Merzi̇fon 05300, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual patient data is not shared in order to protect the individual's privacy and avoid legal repercussions.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07904247
Responsible party
PELİN UYAR (NURSE, Ondokuz Mayıs University) — Principal investigator
First posted
Oct 29, 2026
Start date
Jan 1, 2025
Primary completion
Jan 1, 2026
Completion
Jan 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

İLKNUR A AVCI, PROF
study director · ONDOKUZ MAY UNIVERSTY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion